Stacy Ku
Stock Analyst at TD Cowen
(1.70)
# 3,401
Out of 5,090 analysts
6
Total ratings
50%
Success rate
0.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stacy Ku
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintains: Buy | $45 → $60 | $44.86 | +33.75% | 1 | Oct 23, 2025 | |
| BCRX BioCryst Pharmaceuticals | Reinstates: Buy | $30 | $7.86 | +281.92% | 1 | Oct 15, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | n/a | $29.48 | - | 1 | Jan 7, 2025 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $30 | $16.39 | +83.04% | 1 | Jan 7, 2025 | |
| VRCA Verrica Pharmaceuticals | Maintains: Buy | $150 → $100 | $8.44 | +1,084.83% | 1 | Oct 21, 2024 | |
| ATXS Astria Therapeutics | Initiates: Buy | $35 | $13.10 | +167.18% | 1 | Jul 29, 2024 |
Supernus Pharmaceuticals
Oct 23, 2025
Maintains: Buy
Price Target: $45 → $60
Current: $44.86
Upside: +33.75%
BioCryst Pharmaceuticals
Oct 15, 2025
Reinstates: Buy
Price Target: $30
Current: $7.86
Upside: +281.92%
Centessa Pharmaceuticals
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $29.48
Upside: -
KalVista Pharmaceuticals
Jan 7, 2025
Initiates: Buy
Price Target: $30
Current: $16.39
Upside: +83.04%
Verrica Pharmaceuticals
Oct 21, 2024
Maintains: Buy
Price Target: $150 → $100
Current: $8.44
Upside: +1,084.83%
Astria Therapeutics
Jul 29, 2024
Initiates: Buy
Price Target: $35
Current: $13.10
Upside: +167.18%